Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- GetFeaturedHealth Insurance Now Expands Access to Private PPO Health Insurance PlansHealth Insurance Now has expanded access to private PPO health insurance plans through its national carrier network. The expansion is available to individuals, families, self-employed workers, business owners, early retirees, and other applicants seeking private coverage outside a traditional employer-sponsored plan. The expanded service gives eligible applicants access to a wider range of private PPO health...
- Hagens Berman Sobol Shapiro LLPBBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitBeta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower. National...
- Johns Hopkins USFHP is One of the Highest-Rated Health Plans in the NationJohns Hopkins USFHP earns a 4.5 out of 5 NCQA rating, placing it among the nation’s highest-rated health plans.
- MemorialCareMemorialCare's Long Beach and Saddleback Medical Centers Earn American Heart Association Get With The Guidelines® Gold Plus AwardsNational recognitions highlight excellence in evidence-based stroke and cardiovascular care, improving outcomes and supporting recovery for patients across Southern California. — MemorialCare's Long Beach Medical Center and Saddleback...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors to Seek a Leadership Role Before Deadline on November 2, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may...
- TempraMed Technologies Ltd.TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 RevenueTempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance.The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in TempraMed's history....
- InMed PharmaceuticalsInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity ComplianceInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the...
- Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare CostsTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizophrenia remain on treatment longer while reducing emergency care and healthcare costs compared with other treatment options. The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 53,700 shares of the Company’s common stock (“Stock Options”) and an aggregate of 98,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
- Saratoga Investment CorpSaratoga Investment Corp. Announces CFO Transition and New Leadership AppointmentsSaratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that Henri Steenkamp will step down from his position as Chief Financial Officer, Chief Compliance Officer, Treasurer and Secretary, effective October 31, 2026, for health-related reasons.
- Amneal Announces FDA Approval and Launch of Lanreotide Injection- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.